XENE — Xenon Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $3.30bn
- $2.66bn
- 43
- 29
- 63
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 141 | 177 | 552 | 592 | 638 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.813 | 1.82 | 2.77 | 0.986 | 0.874 |
Prepaid Expenses | |||||
Total Current Assets | 145 | 182 | 559 | 600 | 645 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.59 | 6.88 | 12.5 | 16.9 | 18.8 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 148 | 189 | 572 | 754 | 965 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 43.4 | 14.8 | 14.3 | 22.7 | 27.3 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 55.7 | 17.8 | 22 | 32.6 | 36.9 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 92 | 171 | 550 | 721 | 928 |
Total Liabilities & Shareholders' Equity | 148 | 189 | 572 | 754 | 965 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |